Roche Announces Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression Of Clinical Relapses And Brain Lesions In Patients With Progressive And Relapsing Forms Of MS
Author: Benzinga Newsdesk | April 17, 2024 02:09am
- Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks
- The twice-yearly, 10-minute SC injection has the potential to expand the usage of Ocrevus to treatment centers without IV infrastructure or with IV capacity limitations
- U.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Posted In: RHHBF RHHBY RHHVF